Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
The Journal of Pharmacology and Experimental Therapeutics|July 28, 2010
Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric functionKeith Morrison, Roland Ernst, Patrick Hess, et al.The Journal of Pharmacology and Experimental Therapeutics|March 29, 2018
Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral ArteryKeith Morrison, Franck Haag, Roland Ernst, et al.Journal of Palliative Medicine|April 30, 2014
Families' concerns after bereavement in hospital: what can we learn?Caroline Lebus, Richard A Parker, Keith Morrison, et al.Journal of Medicinal Chemistry|August 21, 2015
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial HypertensionTetsuo Asaki, Keiichi Kuwano, Keith Morrison, et al.The Journal of Pharmacology and Experimental Therapeutics|August 25, 2012
Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary arteryKeith Morrison, Rolf Studer, Roland Ernst, et al.Environmental Science & Technology|October 28, 2023
Impact of a Biological Chelator, Lanmodulin, on Minor Actinide Aqueous Speciation and Transport in the EnvironmentGauthier J-P Deblonde, Keith Morrison, Joseph A Mattocks, et al.Journal of Medicinal Chemistry|February 13, 2024
Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic DiseasesCyrille Lescop, Magdalena Birker, Christine Brotschi, et al.The Journal of Pharmacology and Experimental Therapeutics|May 7, 2017
Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization PotentialJohn Gatfield, Katalin Menyhart, Daniel Wanner, et al.Plos One|February 23, 2024
Potential of APSIS-InSAR for measuring surface oscillations of tropical peatlandsMartha J Ledger, Andrew Sowter, Keith Morrison, et al.Journal of Medicinal Chemistry|February 13, 2024
Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular ScaffoldCyrille Lescop, Christine Brotschi, Jodi T Williams, et al.Pageof 2